Tarcenib 100 mg (Tablet)
Unit Price: ৳ 500.00 (1 x 10: ৳ 5,000.00)
Strip Price: ৳ 5,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Erlotinib |
| Company | Techno drugs ltd |
| Also available as |
Title and Categories
- Tarcenib
- Prescription Medicine
- Cancer Treatment
- Kinase Inhibitor
- Quinazolinamine
Indication
- Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Maintenance Treatment of Locally Advanced or Metastatic NSCLC
- First-line treatment of locally advanced, unresectable, or metastatic pancreatic cancer
- Chemotherapy Maintenance
- EGFR exon 19 deletions or exon 21 substitution mutations
Description
- Chemical Name: N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)4-quinazolinamine
- Reversibly inhibits EGFR kinase activity
- Prevents autophosphorylation of tyrosine residues
- Binds with higher affinity to EGFR exon 19 deletion or exon 21 (L858R) mutations
Dosage and Administration
- Recommended daily dose for NSCLC: 150 mg on an empty stomach
- Recommended daily dose for Pancreatic Cancer: 100 mg in combination with gemcitabine on an empty stomach
- Dose reduction with severe reactions
- Dose adjustment for CYP3A4 inducers and inhibitors
- Dose adjustment for concurrent smoking
Interaction
- Interaction with anticoagulants leading to increased INR and bleeding adverse reactions
- Metabolized predominantly by CYP3A4
- Interaction with CYP3A4 inhibitors and inducers
- Interaction with drugs affecting gastric pH
Side Effects
- Common adverse reactions include rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, and vomiting
- Serious adverse reactions including ILD, renal failure, hepatotoxicity, gastrointestinal perforation, skin disorders, myocardial infarction/ischemia, and others
Pregnancy and Lactation
- Pregnancy Category D
- Potential fetal harm
- Unknown presence in human milk
Precautions and Warnings
- Withhold for ILD and severe renal toxicity
- Monitor liver function for hepatotoxicity
- Discontinue for gastrointestinal perforations and skin disorders
- Increased risk of myocardial infarction (MI) in pancreatic cancer patients
Use in Special Populations
- Safety and effectiveness not established in pediatric patients
- No overall differences in safety or efficacy observed in geriatric use
Overdose Effects
- Tolerated single oral doses up to 1,000 mg in healthy subjects
- Poorly tolerated repeated doses above the recommended dose
- Symptomatic treatment for suspected overdose
Therapeutic Class
- Targeted Cancer Therapy
Storage Conditions
- Store at a temperature not exceeding 30°C
- In a dry place
- Protect from light and moisture